erlotinib
PolandDrugs containing this active substance
-
The medicine is intended for adult patients with advanced non-small cell lung cancer (provided specific EGFR mutations are present) or in the case of metastatic pancreatic cancer (in which case it is used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01XE03
Manufacturer: S.C. Terapia S.A., Sun Pharmaceutical Industries Europe B.V.
-
The medicinal product is used in adult patients with advanced non-small cell lung cancer (provided that specific EGFR mutations are present) and in patients with metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01XE03
Manufacturer: S.C. Terapia S.A., Sun Pharmaceutical Industries Europe B.V.
-
The medicine is used in adult patients for the treatment of advanced non-small cell lung cancer (depending on the cancer cell mutations) and for the treatment of metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01XE03
Manufacturer: S.C. Terapia S.A., Sun Pharmaceutical Industries Europe B.V.
-
The medicine is used in adult patients for the treatment of advanced non-small cell lung cancer (when the cancer cells have specific EGFR mutations) and in the treatment of metastatic pancreatic cancer (in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
Manufacturer: Synthon B.V., Synthon Hispania S.L.
-
The medicine is used in adult patients for the treatment of advanced non-small cell lung cancer (when the cancer cells have specific EGFR mutations) or in cases where previous chemotherapy has not been effective. It may also be used in the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: Synthon B.V., Synthon Hispania S.L.
-
The medicine is intended for adult patients with advanced non-small cell lung cancer (provided specific EGFR mutations are present) and for patients with metastatic pancreatic cancer (in which case it is used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: Synthon B.V., Synthon Hispania S.L.
-
The medicine is intended for adult patients with advanced non-small cell lung cancer (as first-line treatment or when the disease has not responded to chemotherapy) and in the case of metastatic pancreatic cancer (used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
Manufacturer: Synthon B.V., Synthon Hispania S.L.
-
The medicine is intended for adult patients with advanced non-small cell lung cancer (provided that specific EGFR mutations are present) or in the case of metastatic pancreatic cancer (in which case it is used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
Manufacturer: Synthon B.V., Synthon Hispania S.L.
-
The medicinal product is used in adult patients with advanced non-small cell lung cancer and in patients with metastatic pancreatic cancer (in which case it is used in combination with gemcitabine).
Form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
Manufacturer: Synthon B.V., Synthon Hispania S.L.